

relationships in persons with brain metastases (BM) has yet to be identified. **METHODS:** Ninety-three newly diagnosed persons with BM were administered a cognitive battery to assess neurocognitive functioning, mood disturbances, physical functioning, and social support. The Functional Assessment of Cancer Treatment (FACT) scale was used to measure HRQOL. **RESULTS:** Mood and physical function correlated with lower HRQOL in every measured domain. Verbal learning and memory correlated with every FACT subscale except emotional quality of life. Social support also correlated with several HRQOL domains. Stepwise linear regressions revealed that mood was the predominate predictor of HRQOL. Social support, physical functioning, verbal learning, and memory also contribute to HRQOL, but to a lesser extent. **CONCLUSION:** HRQOL is a complex construct affected by mood, physical functioning, and learning and memory. Mood is a domain-independent predictor of HRQOL, while non-mood variables predict HRQOL in domain-specific ways. Thus, multifactorial baseline assessments of persons with BM are encouraged to help mitigate the impact that BM has on HRQOL.

#### 50. RISK OF TRACT RECURRENCE WITH STEREOTACTIC BIOPSY OF BRAIN METASTASES: AN 18-YEAR CANCER CENTER EXPERIENCE

Joseph Carnevale<sup>1,2</sup>, Graham Winston<sup>1</sup>, Jacob Goldberg<sup>1,2</sup>, Cameron Brennan<sup>2</sup>, Viviane Tabar<sup>2</sup>, and Nelson Moss<sup>2</sup>; <sup>1</sup>New York Presbyterian Hospital/Cornell Medical College, New York, NY, USA, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA

**BACKGROUND:** Stereotactic biopsy is increasingly performed on brain metastases (BrM) as improving cancer outcomes drive aggressive multimodality treatment, however the risk of tract recurrence for such biopsies, in both the upfront and recurrent settings, are poorly defined in an era defined by focused-irradiation paradigms. As such, the rate of tract recurrence was evaluated. **METHODS:** A retrospective review was performed to identify stereotactic biopsies performed for BrM at Memorial Sloan Kettering Cancer Center from 2002–2020. Data including surgical indications, tumor type, radiographic characteristics, stereotactic planning, pre- and post-operative CNS-directed and systemic treatments, and clinical courses were collected. Recurrence was evaluated using RANO-BM criteria. **RESULTS:** Four-hundred-and-seventy-nine patients underwent stereotactic intracranial biopsy for any diagnosis (>80% were gliomas or CNS lymphoma). Twenty-two (4.5%) were for pathologically-confirmed viable BrM and 91% (20/22) of these underwent postoperative irradiation with either stereotactic radiotherapy (14/20, 70%; SBRT) in plans that did not specifically target the biopsy tract, or whole-brain irradiation (6/20, 30%; WBRT). Eleven patients (50%) had >=3 months radiographic follow-up (median 11.9; 4.5–30.6), of which 6 (55%) developed discontinuous enhancement along the tract at a median 6.4 months (2.3–17.1) post-biopsy. Of these, 2 had previously been treated with SBRT and were sampled in the setting of diagnostic ambiguity (one additionally with WBRT for small cell carcinoma) and underwent intraoperative laser interstitial thermal therapy (LITT) immediately following biopsy. The remainder were treated with SBRT +/- LITT (n=3 and 4, respectively) following biopsy. Tract recurrences were treated with resection (n=2, both with pathologic confirmation), re-irradiation (n=1) or observation/systemic therapy. **CONCLUSIONS:** In this largest reported series of biopsied BrM, we identify a nontrivial rate, higher than previously described, of recurrence along stereotactic biopsy tracts. As BrM are most commonly treated with focused radiotherapy centered on enhancing tumor margins, consideration should be made to include biopsy tracts where feasible.

#### 51. BRAIN METASTASES FROM ENDOMETRIAL CARCINOMA: TUMOR GENETIC ALTERATIONS IN A CASE SERIES AND META-ANALYSIS

Emily K. Chapman<sup>1</sup>, Nadejda Tsankova<sup>2</sup>, Robert Sebra<sup>3</sup>, and Isabelle M. Germano<sup>1</sup>; <sup>1</sup>Icahn School of Medicine at Mount Sinai - Department of Neurosurgery, New York, NY, USA, <sup>2</sup>Icahn School of Medicine at Mount Sinai - Department of Pathology, New York, NY, USA, <sup>3</sup>Icahn School of Medicine at Mount Sinai - Department of Genetics and Genomic Sciences, New York, NY, USA

**INTRODUCTION:** Endometrial carcinoma (EC) is the most common gynecologic malignancy in the world. While most patients (80%) can be cured with a hysterectomy, the remaining 20% patients who are diagnosed with advanced or recurrent disease have worse survival rates and limited adjuvant treatment options. Discovery of novel target(s)/pathway(s) is needed for better understanding of the pathogenesis and treatment development for this disease. The aim of this study is to review clinical characteristics and genetic signatures of histologically proven EC brain metastasis (BM). **METHODS:** For the period 2000–2019 the medical records of patients with histological diagnosis of EC BM at our Institution were reviewed. Data were collected and analyzed for age, time interval between EC and

EC BM diagnoses, tumor molecular and genetic signatures, and outcome. Immunohistochemistry and sequencing performed as published. A meta-analysis was also performed for the same time period. Data presented as mean±SD and analyzed by t-test and Chi square. **RESULTS:** There were 6 BM from 5 patients meeting our cohort entry criteria and a total 123 cases reported in the literature. The mean age was 57.6 + 11.7 (range 39–69) consistent with reported data. The time interval between EC and EC BM diagnoses was 145.7 + 119.7 (range 33.1–275.7), significantly longer than reported (19.4 + 27.8; range 0–156; p<0.05). All BM in our cohort were metachronous, while only 59% were in the literature. Whereas all FIGO grades are reported in the literature (I=20%; II=6%; III=42%; IV=32%), only I and III were found in our cohort (I=60%, III=40%). Tumor microsatellite instability genes MSH2 and MSH6 were intact, whereas MLH1 and PMS2 showed mutations. PD-L1 expression was low. EC BM genomic reports were not found in the literature. **CONCLUSIONS:** Our study provides insight into the genomic alteration burden on EC BM. Information-driven genomic testing will continue to lead patient-centered therapeutic approaches.

#### 52. BRMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES

Manuel Valiente<sup>1</sup>, Amanda Van Swearingen<sup>2</sup>, Carey Anders<sup>2</sup>, Amos Bairoch<sup>3</sup>, Adrienne Boire<sup>4</sup>, Paula Bos<sup>5</sup>, Diana Cittel<sup>6</sup>, Neta Erez<sup>7</sup>, Gino Ferraro<sup>8</sup>, Dai Fukumura<sup>8</sup>, Brunilde Gril<sup>9</sup>, Meenhard Herlyn<sup>10</sup>, Sheri Holmen<sup>11</sup>, Rakesh Jain<sup>8</sup>, Johanna Joyce<sup>12</sup>, Mihaela Lorger<sup>13</sup>, Joan Massague<sup>14</sup>, Josh Neman<sup>15</sup>, Nicola Sison<sup>16</sup>, Patricia Steeg<sup>7</sup>, Frits Thorsen<sup>17,18</sup>, Leonie Young<sup>19</sup>, Damir Vareslija<sup>19</sup>, Adina Vultur<sup>10,20</sup>, Frances Weis-Garcia<sup>21</sup>, and Frank Winkler<sup>22</sup>; <sup>1</sup>Brain Metastasis Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain, <sup>2</sup>Duke Center for Brain and Spine Metastasis, Duke Cancer Institute, Durham, NC, USA, <sup>3</sup>CALIPHO group, Swiss Institute of Bioinformatics, Geneva, Switzerland, <sup>4</sup>Human Oncology and Pathogenesis Program, Department of Neurology, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>5</sup>Department of Pathology, and Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, VA, USA, <sup>6</sup>Department of Pathology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, <sup>7</sup>Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, <sup>8</sup>E.L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA, <sup>9</sup>National Cancer Institute, Bethesda, MD, USA, <sup>10</sup>Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA, <sup>11</sup>Huntsman Cancer Institute and Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT, USA, <sup>12</sup>University of Lausanne, Ludwig Institute for Cancer Research, Lausanne, Switzerland, <sup>13</sup>Brain Metastasis Research Group, School of Medicine, University of Leeds, Leeds, United Kingdom, <sup>14</sup>Cancer Cell Biology Program, Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>15</sup>Departments of Neurological Surgery, Physiology & Neuroscience, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, <sup>16</sup>Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom, <sup>17</sup>The Molecular Imaging Center, Department of Biomedicine, University of Bergen, Bergen, Norway, <sup>18</sup>Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Key Laboratory of Brain Functional Remodeling, Shandong, Jinan, China, <sup>19</sup>Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland, <sup>20</sup>Molecular Physiology, Institute of Cardiovascular Physiology, University Medical Center, Georg-August-University, Göttingen, Germany, <sup>21</sup>Antibody & Bioresource Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA, <sup>22</sup>Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, and Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

Central nervous system (CNS), notably brain, metastases are most prevalent in lung cancer (20–56% of patients), breast cancer (5–20%) and melanoma (7–16%). Lesions occur in both the brain parenchyma and the meninges. To mechanistically understand CNS metastasis formation and develop preventive and therapeutic strategies, it is essential to use model systems that, as much as possible, faithfully recapitulate the clinical disease process. Furthermore, the complexities of brain metastases dictate that studies should utilize multiple model systems in various stages of brain metastases progression. To facilitate brain metastasis research, 19 laboratories around the world have compiled comprehensive information on their brain metastasis mouse models. Each lab has provided details on the cell lines that they have generated or characterized as being capable of forming metastatic colonies in the brain, as well as principle methodologies of brain metastasis research. This Brain Metastasis Cell Lines Panel (BrMPanel, <https://apps>.

cnio.es/app/BrainMetastasis/CellLines) represents the first of its class and includes information about each cell line, how tropism to the brain was established, and the behavior of each model *in vivo*. The BrMPanel is composed of 60 cell lines, derived from patients (32 cell lines, 53%), mouse (27, 45%) or rat (1, 2%), and represent the three main cancer types that result in brain metastasis: breast cancer (38 cell lines, 63%), lung cancer (8, 13%) and melanoma (14, 23%). This resource is intended to assist investigators in choosing the most suitable model for research on brain metastasis, and is available to the entire scientific community. The ultimate goal of this effort is to facilitate research on this unmet clinical need, to improve models through a collaborative environment, and to promote the exchange of information on these valuable resources. We invite other collaborators to contribute their models to the BrMPanel to grow this resource.

### 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)

Nancy Lin<sup>1</sup>, Rashmi Murthy<sup>2</sup>, Carey Anders<sup>3</sup>, Virginia Borges<sup>4</sup>, Sara Hurvitz<sup>5</sup>, Sherene Loi<sup>6</sup>, Vandana Abramson<sup>7</sup>, Philippe Bedard<sup>8</sup>, Mafalda Oliveira<sup>9</sup>, Amelia Zelnack<sup>10</sup>, Michael DiGiovanna<sup>11</sup>, Thomas Bachelor<sup>12</sup>, A. Jo Chien<sup>13</sup>, Ruth O'Regan<sup>14</sup>, Andrew Wardley<sup>15</sup>, Volkmar Mueller<sup>16</sup>, Lisa Carey<sup>17</sup>, Suzanne McGoldrick<sup>18</sup>, Xuebei An<sup>18</sup>, and Eric Winer<sup>1</sup>; <sup>1</sup>Dana-Farber Cancer Institute, Boston, MA, USA, <sup>2</sup>MD Anderson Cancer Center, Houston, TX, USA, <sup>3</sup>Duke Cancer Institute, Durham/NC, USA, <sup>4</sup>University of Colorado Cancer Center, Aurora, CO, USA, <sup>5</sup>UCLA Medical Center/Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA, <sup>6</sup>Peter MacCallum Cancer Centre, Melbourne, Australia, <sup>7</sup>Vanderbilt University Medical Center, Nashville, TN, USA, <sup>8</sup>University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>9</sup>Hospital Universitario Vall D'Hebron, Barcelona, Spain, <sup>10</sup>Northside Hospital, Sandy Springs, GA, USA, <sup>11</sup>Yale Cancer Center, New Haven, CT, USA, <sup>12</sup>Centre Léon Bérard, Lyon, France, <sup>13</sup>University of California at San Francisco, San Francisco, CA, USA, <sup>14</sup>Carbone Cancer Center / University of Wisconsin, Madison, WI, USA, <sup>15</sup>The Christie NHS Foundation Trust, Manchester Academic Health Science Centre & Division of Cancer Sciences, School of Medical Sciences, University of Manchester, Manchester, United Kingdom, <sup>16</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany, <sup>17</sup>UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA, <sup>18</sup>Seattle Genetics, Bothell, WA, USA

**BACKGROUND:** HER2CLIMB (NCT02614794) primary results have been reported previously (Murthy, NEJM 2019). We report results of exploratory efficacy analyses in pts with brain metastases (BM). **METHODS:** All HER2+ MBC pts enrolled had a baseline brain MRI. Pts with BM were eligible and randomized 2:1 to receive tucatinib (TUC) or placebo, in combination with trastuzumab and capecitabine. Efficacy analyses were performed by applying RECIST 1.1 to the brain based on investigator evaluation. CNS-PFS and OS were evaluated in BM pts overall. Intracranial (IC) confirmed ORR-IC and DOR-IC were evaluated in BM pts with measurable IC disease. After isolated brain progression, pts could continue study therapy until second progression, and time from randomization to second progression or death was evaluated. **RESULTS:** Overall, 291 pts (48%) had BM at baseline: 198 (48%) in the TUC arm and 93 (46%) in the control arm. There was a 68% reduction in risk of CNS-PFS in the TUC arm (HR: 0.32; P<0.0001). Median CNS-PFS was 9.9 mo in the TUC arm vs 4.2 mo in the control arm. Risk of overall death was reduced by 42% in the TUC arm (OS HR: 0.58; P=0.005). Median OS was 18.1 mo vs 12.0 mo. ORR-IC was higher in the TUC arm (47.3%) vs the control arm (20.0%). Median DOR-IC was 6.8 mo vs 3.0 mo. In pts with isolated brain progression who continued study therapy after local treatment (n=30), risk of second progression or death was reduced by 71% (HR: 0.29), and median time from randomization to second progression or death was 15.9 mo vs 9.7 mo, favoring the TUC arm. **CONCLUSIONS:** In pts with previously treated HER2+ MBC with BM, TUC in combination with trastuzumab and capecitabine doubled the ORR-IC, reduced risk of IC progression or death by two-thirds and reduced risk of death by nearly half.

### 54. TGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES

Daniel Doheny, Sherona Sirkisoon, Tadas Rimkus, Dongqin Zhu, Noah Aguayo, Marlyn Anguelov, Sara Manore, Angelina Regua, Alexandra Thomas, Adrianna Henson-Masters, Roy Strowd, and Hui-Wen Lo; Wake Forest School of Medicine, Winston-Salem, NC, USA

Breast cancer is the second leading cause of brain metastases in women; patients with breast cancer brain metastasis (BCBM) survive an average of 6–18 months following diagnosis. Cancer stem cells are thought to be one of the driving forces behind distant metastasis, treatment resistance, and late-stage recurrence. The hedgehog-smoothened pathway has been identified as

an important mediator of breast cancer stem cells (BCSC); however, FDA-approved therapies targeting smoothened have demonstrated limited clinical efficacy in breast cancer. Despite advances made in understanding BCSC, it is still challenging to effectively target BCSC underscoring the need to identify and inhibit novel mediators of BCSC for treating BCBM patients. Our laboratory recently reported that truncated glioma-associated oncogene homolog 1 (tGLI1) promotes preferential metastasis to the brain in breast cancer by activating BCSC and astrocytes in the tumor microenvironment (Oncogene 39:64–78, 2020). tGLI1 was discovered in our laboratory as an alternatively spliced GLI1 that functions as a tumor-specific gain-of-function transcription factor and terminal effector of the hedgehog pathway. We found that tGLI1 knockdown abrogated BCBM, providing the rationale to therapeutically target tGLI1. Cell-based chemical screens followed by validations demonstrated that ketoconazole, an FDA-approved azole antifungal, specifically inhibits tGLI1 leading to suppression of BCSC *in vitro* and BCBM *in vivo*. Based on these data, we opened a window-of-opportunity study in patients with BCBM to determine if ketoconazole penetrates the blood-brain barrier (BBB) and alters tGLI1 signaling in humans (NCT03796273). Preliminary sample analysis has confirmed tGLI1 expression in collected BCBM samples. To help identify more effective tGLI1 inhibitors, we screened 63 azole compounds for tGLI1-selectivity and identified four additional compounds as potential tGLI1 inhibitors. Animal studies were performed to compare the efficacy of these four compounds with ketoconazole in suppressing BCBM. Collectively, these data establish tGLI1 as an actionable target for BCBM.

### 55. A RANDOMIZED, MULTICENTER PHASE III TRIAL OF SURGERY PLUS STEREOTACTIC RADIOSURGERY (SRS) COMPARED WITH SURGERY PLUS PERMANENTLY IMPLANTED COLLAGEN TILE BRACHYTHERAPY (CTBT) FOR RESECTABLE METASTATIC BRAIN TUMORS-PROTOCOL IN PROGRESS

Jeffrey Weinberg, MD<sup>1</sup>, Mary Frances McAleer, MD, PhD<sup>2</sup>, Hussein Tawbi, MD, PhD<sup>3</sup>, and Frederick Lang, MD<sup>1</sup>; <sup>1</sup>The University of Texas MD Anderson Cancer Center, Dept of Neurosurgery, Houston, TX, USA, <sup>2</sup>The University of Texas MD Anderson Cancer Center, Dept of Radiation Oncology, Houston, TX, USA, <sup>3</sup>The University of Texas MD Anderson Cancer Center, Dept of Melanoma Medical Oncology, Houston, TX, USA

**BACKGROUND:** Resection (R) followed by single or multi-fraction stereotactic radiosurgery (SRS) lowers resection bed recurrence compared to R alone. Nevertheless for larger brain metastasis (>2.5 cm) 12-month recurrence rates after R+SRS can exceed 20–30%. Aiming to improve outcomes, a permanently implanted collagen tile brachytherapy (CTBT) device (GammaTile, GT Medical Technologies, Tempe AZ) utilizing Cs-131 was developed, hypothesizing that immediate adjuvant radiotherapy (RT) and/or RT dose intensification could improve outcomes. The device received FDA clearance for this indication, based on a single-arm pre-commercial study and in early commercial use due to the excellent safety and local control of R+CTBT. It is hypothesized that R+CTBT will increase the time to post-resection-recurrence, while prolonging survival and reducing the impact on functional and neurocognitive status compared to R+SRS. **STUDY DESIGN:** Multicenter, randomized, comparison trial. Patients with resectable, previously untreated “index” brain metastases measuring >2.5–5 cm and 0–3 other tumors will be preoperatively randomized 1:1 to undergo either R+ SRS or R+CTBT to the index lesion; unresected tumors in both groups will receive SRS. Planned sample size is 160 from ~5 sites; accrual to start in Q3-2020. Primary endpoint is surgical bed-recurrence free survival. Secondary endpoints include overall survival, quality of life (Functional Assessment of Cancer Therapy-Brain, Linear Analog Self-Assessment), neurocognition (Hopkins Verbal Learning Test, Trail Making Tests, Mini-Mental Status Exam, Controlled Oral Word Association), functional decline (Karnofsky Performance Scale, Barthel-ADL), and adverse events. Follow-up will be at 1,3,6,9, and 12 months, then q 6 months through 5 years. **CONCLUSIONS:** This will be the first randomized trial comparing R+SRS versus R+CTBT delivered by Cs-131 sources in permanently implanted resorbable collagen tile carriers. Primary and secondary outcome measures will be captured to elucidate the potential risks and benefits of these two differing approaches for patients with metastatic brain tumors.

### 56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS

Wulin Jiang<sup>1</sup>, Alain Valdivia<sup>1</sup>, Alison Mercer-Smith<sup>1</sup>, Carey Anders<sup>2</sup>, and Shawn Hingtgen<sup>1</sup>; <sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, <sup>2</sup>Duke University, Durham, NC, USA

**INTRODUCTION:** Leptomeningeal carcinomatosis remains one of the most lethal forms of central nervous system metastasis, with a median survival of only 4 months. Effective new therapies are urgently needed to treat this highly aggressive cancer. In this study, we used models of both prophyl-